SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

GRI Bio, Inc.
Date: Jan. 30, 2026 · CIK: 0001824293 · Accession: 0000000000-26-001119

Offering / Registration Process Regulatory Compliance Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-293065

Date
January 30, 2026
Author
W. Marc Hertz, Ph.D.
Form
UPLOAD
Company
GRI Bio, Inc.

Letter

January 30, 2026 W. Marc Hertz, Ph.D. President and Chief Executive Officer GRI Bio, Inc. 2223 Avenida de la Playa, #208 La Jolla, CA 92037 Re:GRI Bio, Inc. Registration Statement on Form S-3 Filed January 30, 2026 File No. 333-293065 Dear W. Marc Hertz Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jessica Zhang, Esq.

Show Raw Text
January 30, 2026
W. Marc Hertz, Ph.D.
President and Chief Executive Officer
GRI Bio, Inc.
2223 Avenida de la Playa, #208
La Jolla, CA 92037
Re:GRI Bio, Inc.
Registration Statement on Form S-3
Filed January 30, 2026
File No. 333-293065
Dear W. Marc Hertz Ph.D.:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jessica Zhang, Esq.